Patent provides IP protection for lead product candidate eltoprazine for the treatment of Parkinson\'s Disease - SAN FRANCISCO, CA, and GENEVA, SWITZERLAND - (http://www.financialnewsmedia.com News Alert) - Amarantus BioScience Holdings, Inc. (OTCQB:AMBSD), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent No. 9,066,903 entitled, "Pharmacological Treatment of Parkinson\'s Disease." The patent covers methods for the administration of eltoprazine, in combination with the anti-Parkinson's drug, levodopa (L-DOPA), for the treatment of Parkinson\'s disease.
\"We are very pleased with the issuance by the USPTO of the patent covering the use of eltoprazine in treating patients with Parkinson\'s disease receiving L-DOPA and who suffer from L-DOPA induced dyskinesia. This new issuance helps the Company continue to build our intellectual property estate for eltoprazine," said Gerald E. Commissiong, President & CEO of Amarantus. "The Phase 2b clinical study has commenced with patient screening progressing well and now rapidly heading into the first randomization. We expect the first patient to be randomized in the trial very shortly. Initiation of patient screening is an important step forward in terms of ramping up the trial initiation process. We believe eltoprazine has tremendous potential to address a significant unmet therapeutic need or individuals with Parkinson\'s disease."
Eltoprazine is a small molecule 5HT1A/1B partial agonist and the Amarantus is currently preparing to commence Phase 2b clinical development for the treatment of Parkinson\'s disease levodopa-induced dyskinesia (PD-LID). PD-LID is an abnormal involuntary, movement disorder resulting from prolonged levodopa-based therapy, the most commonly prescribed treatment for Parkinson\'s disease. PD-LID occurs in approximately 60-80% of Parkinson's disease patients and is one of the most difficult problems facing people with the disease. This dyskinesia can be severely disabling and impact quality of life by prohibiting the ability to perform routine daily functions.
Amarantus has initiated a multi-center, 60-subject Phase 2b study in individuals with PD-LID. The study is a double-blind, placebo-controlled,...
$AMBSD News - Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease
June 30, 2015 at 09:14 AM EDT
